Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;12(9):2161-2171.
doi: 10.1007/s13555-022-00792-0. Epub 2022 Aug 26.

Pretreatment with an Aerosol Foam Containing Calcipotriene and Betamethasone Strongly Improves the Efficacy of Narrow-Band UVB Phototherapy

Gaetano Licata  1 , Mariachiara Arisi  2 , Marina Venturini  2 , Mariateresa Rossi  2 , Cesare Tomasi  3 , Irene Calzavara-Pinton  2 , Piergiacomo Calzavara-Pinton  2
Affiliations

Pretreatment with an Aerosol Foam Containing Calcipotriene and Betamethasone Strongly Improves the Efficacy of Narrow-Band UVB Phototherapy

Gaetano Licata et al. Dermatol Ther (Heidelb). 2022 Sep.

Abstract

Background: Narrow-band (NB) UVB has been combined with a number of topical treatments. However, there have been no specific data regarding treatment results of a fixed combination of calcipotriene 50 μg/g plus betamethasone 0.5 mg/g aerosol foam (Cal/BD) combined with NB-UVB phototherapy so far.

Objectives: To assess the efficacy of Cal/BD foam coupled to twice-weekly NB-UVB and whether this combined regimen requires fewer UVB treatments and a lower cumulative UVB dose compared to phototherapy alone.

Methods: This cross-sectional, prospective, parallel-group study enrolled 187 consecutive moderate-to-severe psoriatic patients who were allocated to two groups in a 1:2 ratio. The overall duration of the treatment cycle was 12 weeks. At baseline and after 2, 4, 8 and 12 weeks, we registered the modified (not considering head lesions) PASI, the number of Cal/BD applications, the NRS score for itching and the adverse effects.

Results: The combined regimen was more effective in clearing psoriasis [final mPASI: 2.1 (0; 8.2) versus 4.4 (0; 19.6); p < 0.01] and reducing itching [(final NRS score for itching: 0 (0; 3) versus 1 (0; 4); p < 0.01]. Fewer exposures [12 (4; 20) versus 24 (8; 24); p < 0.01] and a lower cumulative UVB dose [6.1 (5.4; 9.3) J cm-2 versus 13.1 (9.8; 19.7) J cm-2; p < 0.01] were required. A higher number of patients achieved complete clearance [47 (74.6%) versus 58 (46.8%) patients (p < 0.001)]. Both treatments were well tolerated without acute adverse effects.

Conclusion: Cal/BD + NB-UVB is a very effective treatment that produces a rapid improvement in clinical lesions and itching and can be considered a valuable alternative to systemic treatments for psoriasis.

Keywords: Betamethasone; Calcipotriene; Combined regimen; NB-UVB; Narrow-band UVB phototherapy; Psoriasis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Box plot of median (IQR) mPASI at baseline (T0) and after 4 (T2), 8 (T3) and 12 (T4) weeks in the two groups. In both groups, mPASI values at T2, T3 and T4 were always significantly lower (p < 0.001, Mann–Whitney test) in comparison to the baseline mPASI value. The symbol * indicates an outlier, i.e. a data point that is located outside the whiskers of the box
Fig. 2
Fig. 2
A psoriatic plaque at baseline (a); a decrease in scaling and infiltrate was observed after 2 weeks of application of Cal/BD foam (b), and only mild erythema persisted after 2 further weeks of combined treatment with Cal/BD and phototherapy (c)
Fig. 3
Fig. 3
Median NRS scores for itching at baseline (T0) and after 4 (T2), 8 (T3) and 12 (T4) weeks in the two groups
See this image and copyright information in PMC

References

    1. Nast A, Spuls PI, van der Kraaij G, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris—update apremilast and secukinumab—EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol JEADV. 2017;31:1951–1963. doi: 10.1111/jdv.14454. - DOI - PubMed
    1. Bagel J, Gold LS. Combining topical psoriasis treatment to enhance systemic and phototherapy: a review of the literature. J Drugs Dermatol. 2017;16(12):1209–1222. - PubMed
    1. Zeichner JA, Lebwohl MG, Menter A, et al. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis. 2010;86(3 Suppl):5–32. - PubMed
    1. Svendsen MT, Jeyabalan J, Andersen KE, Andersen F, Johannessen H. Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. J Dermatolog Treat. 2017;28(5):374–383. doi: 10.1080/09546634.2016.1254331. - DOI - PubMed
    1. Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34–41. - PMC - PubMed

LinkOut - more resources